In addition, PEGylated IL-10 has been found to induce systemic immune activation in melanoma patients, and its use in combination with Nivolumab induced a manageable toxicity and preliminary anti-tumor activity in melanoma patients (10% patients with objective responses) [59]. This evidence concerns the gene IL10 and melanoma.